Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
Full Title of Study: “A Single Patient Protocol for TNB-383B, a Bispecific Antibody Targeting BCMA in a Subject With Relapsed/Refractory Multiple Myeloma”
- Study Type: Expanded Access
- Drug: TNB-383B
- TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
Participating in This Clinical Trial
- Adequate bone marrow function – eGFR ≥ 30 mL/min – Total bilirubin ≤ 1.5 × upper limit of normal (ULN) – Serum calcium (corrected for albumin) at or below the ULN range Exclusion Criteria:
- Candidate for treatment regimens known to provide clinical benefit in MM – Active infection requiring parenteral anti-infective treatment – Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
- Lead Sponsor
- TeneoOne Inc.
- Provider of Information About this Clinical Study
- Overall Official(s)
- Ben Buelow, Study Chair, Amgen
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.